Cheviot Value Management LLC reduced its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 0.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,108 shares of the healthcare product maker’s stock after selling 95 shares during the quarter. Cheviot Value Management LLC’s holdings in Abbott Laboratories were worth $1,570,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Unique Wealth Strategies LLC acquired a new position in Abbott Laboratories in the second quarter valued at $28,000. Transcendent Capital Group LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at $29,000. Richardson Financial Services Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at $29,000. Redmont Wealth Advisors LLC acquired a new position in Abbott Laboratories in the first quarter valued at $30,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in Abbott Laboratories during the second quarter valued at about $32,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Abbott Laboratories
In related news, CEO Robert B. Ford sold 141,679 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the transaction, the chief executive officer now owns 220,059 shares of the company’s stock, valued at $25,617,068.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.10% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Abbott Laboratories Price Performance
Shares of NYSE ABT opened at $114.78 on Tuesday. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The business has a 50-day moving average of $110.74 and a 200-day moving average of $108.41. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.68 and a quick ratio of 1.18. The company has a market capitalization of $199.68 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 2.90 and a beta of 0.72.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. The firm had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.37 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. Abbott Laboratories’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.08 earnings per share. On average, equities analysts anticipate that Abbott Laboratories will post 4.66 EPS for the current fiscal year.
Abbott Laboratories Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date is Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 68.54%.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Comparing and Trading High PE Ratio Stocks
- The Average 401k Balance by Age Explained
- About the Markup Calculator
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- How to Use the MarketBeat Dividend Calculator
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.